Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Amortizatization of Intangibles (2020 - 2025)

Tarsus Pharmaceuticals has reported Amortizatization of Intangibles over the past 6 years, most recently at -$3.6 million for Q4 2025.

  • Quarterly results put Amortizatization of Intangibles at -$3.6 million for Q4 2025, down 1878.5% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 691.4% YoY), and the annual figure for FY2025 was $1.0 million, up 100.0%.
  • Amortizatization of Intangibles for Q4 2025 was -$3.6 million at Tarsus Pharmaceuticals, down from $200000.0 in the prior quarter.
  • Over the last five years, Amortizatization of Intangibles for TARS hit a ceiling of $200000.0 in Q4 2024 and a floor of -$3.6 million in Q4 2025.
  • Median Amortizatization of Intangibles over the past 5 years was $100000.0 (2023), compared with a mean of -$168357.1.
  • Biggest five-year swings in Amortizatization of Intangibles: soared 258.73% in 2023 and later crashed 1878.5% in 2025.
  • Tarsus Pharmaceuticals' Amortizatization of Intangibles stood at -$87000.0 in 2021, then grew by 27.59% to -$63000.0 in 2022, then soared by 258.73% to $100000.0 in 2023, then skyrocketed by 100.0% to $200000.0 in 2024, then crashed by 1878.5% to -$3.6 million in 2025.
  • The last three reported values for Amortizatization of Intangibles were -$3.6 million (Q4 2025), $200000.0 (Q3 2025), and $200000.0 (Q2 2025) per Business Quant data.